Sarepta Therapeutics (SRPT)
(Delayed Data from NSDQ)
$142.24 USD
-0.80 (-0.56%)
Updated Jul 31, 2024 04:00 PM ET
After-Market: $142.35 +0.11 (0.08%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth D Momentum F VGM
Brokerage Reports
Sarepta Therapeutics, Inc. [SRPT]
Reports for Purchase
Showing records 661 - 669 ( 669 total )
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Reports FY 2Q12 Earnings; Several Upcoming Catalysts in 2H12
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of July 29
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Increasing Price Target to $26 - Eteplirsen Shows Statistically Significant Clinical Benefit in 6-Minute Walk
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Unprecedented Benefit in DMD Patients Reported By Use of Eteplirsen in Study 202
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Unprecedented Benefit in DMD Patients Reported By Use of Eteplirsen in Study 202
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
100% Survival Reported in a Non-human Primate Study of AVI-7288 for Marburg Virus
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
100% Survival Reported in a Non-human Primate Study of AVI-7288 for Marburg Virus
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M